720681Clinical Validation of Novel Patient Recruitment PlatformClosedGRD Development of PrototypeInnovate UKClinical trials (CTs) are essential to evaluate scientific discoveries but are becoming unsustainable, threatening to deprive patients & healthcare providers of essential new therapies, due to increasing complexity of trial protocol designs . From 2000 to 2010, patient CT eligibility criteria increased by 200% per protocol, causing declining patient recruitment rates & rising CT costs (globally per-patient, CT costs have risen by 70% since 2008). Tomorrows Medicines Ltd (TM) have confirmed mkt need & demonstrated tech viability for YourTreatmentChoices.com (YTC), a digital patient recruitment platform which overcomes the heavy screening burden of current digital recruitment methods. YTC has been designed for 1 condition (bowel cancer), to achieve its full mkt potential (£3.8bn global CT recruitment industry), TM must integrate “advanced self-screening software” to ensure the back-end of the platform is scalable, flexible & can be applied to any condition. Additionally, initial user testing by research nurses has highlighted an opportunity for improving platform efficiency by reusing patient data to automatically match them to alternate CTs. This can be achieved via a “novel automated matching system” predicted to reduce patient fall out rate from 70% currently to 35% leading to significant advertising cost savings. TM will develop, integrate & validate in a clinical setting the proposed “advanced self-screening software” & “novel automated matching system”. To achieve a step change in YTC functionality, TM must address developmental challenges incl. data security, efficient execution time & reliability of algorithms. End users recognise the benefits of YTC & as such, Takeda & Leukaemia & Lymphoma Research (L&LR) will support the CTs planned for the project in-kind. Resulting CT data will be utilised to demonstrate mkt application & efficiency to accelerate uptake by paying end users (sponsors & CROs); mkt launch expected 2016.